{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:24:58Z","timestamp":1775841898054,"version":"3.50.1"},"reference-count":41,"publisher":"European Respiratory Society (ERS)","issue":"6","license":[{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","award":["1.R016.18"],"award-info":[{"award-number":["1.R016.18"]}],"id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2025,4,28]]},"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In the era of highly effective modulator therapies, pulmonary function, the number and severity of exacerbations and the quality of life of people with cystic fibrosis (CF) are improving significantly. The polymeric immunoglobulin receptor (pIgR)\/IgA system, which is impaired in CF, protects the respiratory epithelium against harmful inhaled pathogens. The aims of this interventional prospective study were 1) to assess IgA mucosal immunity in bodily fluids from people with CF before and after elexacaftor\/tezacaftor\/ivacaftor (ETI) initiation, and 2) to investigate the mucosal IgA response in urine from people with CF compared with healthy controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We quantified by ELISA the different agents comprising the pIgR\/IgA system (total IgA, IgA1, IgA2, secretory IgA (S-IgA), secretory component of pIgR, and specific IgA against\n                      <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                      or against staphylococcal enterotoxin B in sputum, serum, and urine from 57 people with CF and 30 healthy controls.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Hyperactivation of the pIgR\/IgA system was maintained under ETI, with no significant differences between total IgA, IgA1, IgA2, S-IgA nor secretory component levels in sputum, serum and urine from people with CF before and after ETI initiation, except for an increase in urine S-IgA after treatment. We demonstrate an activation of the mucosal immune system in the urinary tract of people with CF, with a higher level of total IgA (p=0.0141) compared with healthy controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Even with highly effective modulator therapy, the pIgR\/IgA system remains hyperactivated after \u22653 months of treatment, suggesting that at this time the local IgA immunity is always impaired.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/23120541.01369-2024","type":"journal-article","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T12:30:11Z","timestamp":1750336211000},"page":"01369-2024","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Immunoglobulin A mucosal immunity in people with cystic fibrosis shortly after initiation of highly effective modulator therapy"],"prefix":"10.1183","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3343-8872","authenticated-orcid":false,"given":"Ang\u00e9lique","family":"Mottais","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyu Alessia","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Detry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryl\u00e8ne","family":"Lecocq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Goubau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Berardis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Hox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7133-1788","authenticated-orcid":false,"given":"Antoine","family":"Froidure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Pilette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Gohy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"81","published-online":{"date-parts":[[2025,6,19]]},"reference":[{"key":"2025111002401423000_11.6.01369-2024.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32542-3"},{"key":"2025111002401423000_11.6.01369-2024.2","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.jcf.2021.01.012","article-title":"Neutrophil dysfunction in cystic fibrosis","volume":"20","author":"Yonker","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2025111002401423000_11.6.01369-2024.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2216474"},{"key":"2025111002401423000_11.6.01369-2024.4","unstructured":"Cystic Fibrosis Foundation . Cystic Fibrosis Foundation 2023 Patient Registry Annual Data Report. Bethesda, Cystic Fibrosis Foundation, 2024."},{"key":"2025111002401423000_11.6.01369-2024.5","unstructured":"Zolin A , Adamoli A , Bakkeheim E , et al. ECFSPR Annual Report 2022; 2024. www.ecfs.eu\/"},{"key":"2025111002401423000_11.6.01369-2024.6","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.2009.abs"},{"key":"2025111002401423000_11.6.01369-2024.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32597-8"},{"key":"2025111002401423000_11.6.01369-2024.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908639"},{"key":"2025111002401423000_11.6.01369-2024.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01609-4"},{"key":"2025111002401423000_11.6.01369-2024.10","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 open-label study of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2025111002401423000_11.6.01369-2024.11","doi-asserted-by":"crossref","first-page":"e15756","DOI":"10.1016\/j.heliyon.2023.e15756","article-title":"Elexacaftor \u2013 tezacaftor \u2013 ivacaftor treatment improves systemic infection parameters and Pseudomonas aeruginosa colonization rate in patients with cystic fibrosis a monocentric observational study","volume":"9","author":"Schnell","year":"2023","journal-title":"Heliyon"},{"key":"2025111002401423000_11.6.01369-2024.12","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1038\/s41467-025-57667-z","article-title":"Structure and function relationships of mucociliary clearance in human and rat airways","volume":"16","author":"Roth","year":"2025","journal-title":"Nat Commun"},{"key":"2025111002401423000_11.6.01369-2024.13","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.3390\/cells10123603","article-title":"Immunoglobulin A mucosal immunity and altered respiratory epithelium in cystic fibrosis","volume":"10","author":"Gohy","year":"2021","journal-title":"Cells"},{"key":"2025111002401423000_11.6.01369-2024.14","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1699-0463.1992.tb00879.x","article-title":"Mucosal immunity to Pseudomonas aeruginosa alginate in cystic fibrosis","volume":"100","author":"Pedersen","year":"1992","journal-title":"APMIS"},{"key":"2025111002401423000_11.6.01369-2024.15","doi-asserted-by":"crossref","first-page":"102974","DOI":"10.1016\/j.ebiom.2020.102974","article-title":"Lung immunoglobulin A immunity dysregulation in cystic fibrosis","volume":"60","author":"Collin","year":"2020","journal-title":"EBioMedicine"},{"key":"2025111002401423000_11.6.01369-2024.16","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.93.01080701"},{"key":"2025111002401423000_11.6.01369-2024.17","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.150.2.8049828"},{"key":"2025111002401423000_11.6.01369-2024.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2016.09.064"},{"key":"2025111002401423000_11.6.01369-2024.19","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-1993(02)00141-8"},{"key":"2025111002401423000_11.6.01369-2024.20","doi-asserted-by":"publisher","DOI":"10.1183\/20734735.042912"},{"key":"2025111002401423000_11.6.01369-2024.21","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201203-0507OC"},{"key":"2025111002401423000_11.6.01369-2024.22","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.jcf.2021.11.003","article-title":"A restructuring of microbiome niche space is associated with elexacaftor\u2013tezacaftor\u2013ivacaftor therapy in the cystic fibrosis lung","volume":"21","author":"Sosinski","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2025111002401423000_11.6.01369-2024.23","doi-asserted-by":"crossref","first-page":"e0145422","DOI":"10.1128\/spectrum.01454-22","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor therapy on the cystic fibrosis airway microbial metagenome","volume":"10","author":"Pallenberg","year":"2022","journal-title":"Microbiol Spectr"},{"key":"2025111002401423000_11.6.01369-2024.24","doi-asserted-by":"crossref","first-page":"2202163","DOI":"10.1183\/13993003.02153-2022","article-title":"Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis","volume":"62","author":"Schaupp","year":"2023","journal-title":"Eur Respir J"},{"key":"2025111002401423000_11.6.01369-2024.25","doi-asserted-by":"crossref","first-page":"e0078724","DOI":"10.1128\/spectrum.00787-24","article-title":"Cystic fibrosis pathogens persist in the upper respiratory tract following initiation of elexacaftor\/tezacaftor\/ivacaftor therapy","volume":"12","author":"Hilliam","year":"2024","journal-title":"Microbiol Spectr"},{"key":"2025111002401423000_11.6.01369-2024.26","doi-asserted-by":"crossref","first-page":"e20230079","DOI":"10.1084\/jem.20230079","article-title":"Immunomolecular and reactivity landscapes of gut IgA subclasses in homeostasis and inflammatory bowel disease","volume":"221","author":"Tejedor-Vaquero","year":"2024","journal-title":"J Exp Med"},{"key":"2025111002401423000_11.6.01369-2024.27","doi-asserted-by":"publisher","DOI":"10.1016\/S0954-6111(08)80014-5"},{"key":"2025111002401423000_11.6.01369-2024.28","doi-asserted-by":"crossref","first-page":"284","DOI":"10.4049\/jimmunol.114.1_Part_2.284","article-title":"Increased risistance of immunoglobulin A dimers to proteolytic degradation after binding of secretory component","volume":"114","author":"Lindh","year":"1975","journal-title":"J Immunol"},{"key":"2025111002401423000_11.6.01369-2024.29","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200305-619OC"},{"key":"2025111002401423000_11.6.01369-2024.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2021.09.017"},{"key":"2025111002401423000_11.6.01369-2024.31","doi-asserted-by":"publisher","DOI":"10.1136\/adc.65.3.259"},{"key":"2025111002401423000_11.6.01369-2024.32","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1128\/jcm.30.7.1848-1855.1992","article-title":"Antibody responses to lipid A, core, and O sugars of the Pseudomonas aeruginosa lipopolysaccharide in chronically infected cystic fibrosis patients","volume":"30","author":"Kronborg","year":"1992","journal-title":"J Clin Microbiol"},{"key":"2025111002401423000_11.6.01369-2024.33","first-page":"23","article-title":"Immune complexes and humoral response to Pseudomonas aeruginosa in cystic fibrosis","volume":"121","author":"Moss","year":"1980","journal-title":"Am Rev Respir Dis"},{"key":"2025111002401423000_11.6.01369-2024.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2012.07.001"},{"key":"2025111002401423000_11.6.01369-2024.35","doi-asserted-by":"publisher","DOI":"10.1136\/adc.53.8.631"},{"key":"2025111002401423000_11.6.01369-2024.36","doi-asserted-by":"publisher","DOI":"10.1136\/adc.63.10.1222"},{"key":"2025111002401423000_11.6.01369-2024.37","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jped.2013.02.007","article-title":"The impact of cystic fibrosis on the immunologic profile of pediatric patients","volume":"89","author":"Bernardi","year":"2013","journal-title":"J Pediatr"},{"key":"2025111002401423000_11.6.01369-2024.38","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2169\/internalmedicine1962.28.189","article-title":"Secretory IgA(S-IgA) levels in sera from patients with diffuse panbronchiolitis","volume":"28","author":"Noda","year":"1989","journal-title":"Jpn J Med"},{"key":"2025111002401423000_11.6.01369-2024.39","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1186\/s13054-024-05127-3","article-title":"Airway epithelium damage in acute respiratory distress syndrome","volume":"28","author":"Gerard","year":"2024","journal-title":"Crit Care"},{"key":"2025111002401423000_11.6.01369-2024.40","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1016\/j.ajpath.2019.06.015","article-title":"Localization and regulation of polymeric Ig receptor in healthy and diseased human kidney","volume":"189","author":"Krawczyk","year":"2019","journal-title":"Am J Pathol"},{"key":"2025111002401423000_11.6.01369-2024.41","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jcf.2021.07.005","article-title":"Urinary tract infections in cystic fibrosis patients","volume":"21","author":"Reasoner","year":"2022","journal-title":"J Cyst Fibros"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.01369-2024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T10:40:31Z","timestamp":1762771231000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.01369-2024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,19]]},"references-count":41,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,11,10]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1183\/23120541.01369-2024"],"URL":"https:\/\/doi.org\/10.1183\/23120541.01369-2024","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,19]]}}}